Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from REGN

Regeneron Pharmaceuticals Earnings Preview: What to Expect

Regeneron Pharmaceuticals will release its second-quarter earnings next month, and analysts anticipate a double-digit profit dip.

Barchart

The Saturday Spread: Leveraging Applied Game Theory to Find Probabilistically Attractive Trades

Summary: Options traders seeking to extract quick profits may want to keep an eye on WMB, REGN and IOT this week.

Barchart

Regeneron Pharmaceuticals Stock: Is Wall Street Bullish or Bearish?

Despite Regeneron Pharmaceuticals' underperformance relative to the broader market over the past year, Wall Street analysts maintain a bullish outlook about the stock’s prospects.

Barchart

From analysis to the latest developments in health,
read the most diverse news in one place.

Big Dippers: 3 Stocks Near 1-Year Lows That Could Surge in 2025

CCOI, AESI, and REGN are near one-year lows but remain favored by analysts; watch these stocks for future growth potential.

MarketBeat

Best Biotech Stocks to Buy in 2025

Discover the best biotech stocks of 2025, including top performers like Vertex and Regeneron, driven by clinical breakthroughs and strong investor momentum.

MarketBeat

What to Expect From Regeneron's Next Quarterly Earnings Report

Regeneron is gearing up to report its first-quarter results later this month, with market expectations pointing to a double-digit decline in earnings.

Barchart

Is Regeneron Pharmaceuticals Stock Underperforming the Dow?

Regeneron Pharmaceuticals has underperformed the Dow over the past year, but analysts are highly optimistic about the stock’s prospects.

Barchart

Read news from The Economist, FT, and more,
with one subscription

Regeneron: Is It the Perfect Biotech Stock for Value and Growth?

Regeneron is trading at historically low valuations as its Dupixent blockbuster drug could get a 30% increase in TAM if the FDA approves its use in COPD.

MarketBeat

Regeneron Pharmaceuticals Stock: Analyst Estimates & Ratings

Despite Regeneron Pharmaceuticals’ underperformance relative to the broader market over the past year, Wall Street analysts maintain a bullish outlook about the stock’s prospects.

Barchart

3 Precision Medicine Stocks That Could Transform Healthcare

With the robust demand for personalized medicines and the growing adoption of digital technology, the precision medicine industry is expected to witness significant growth and expansion. Hence, it could be wise to invest in quality precision medicine stocks Bristol-Myers Squibb (BMY), Regeneron Pharmaceuticals (REGN), and Illumina (ILMN) that are transforming…

StockNews.com

3 Genomic Stocks at the Forefront of Precision Medicine

Precision medicine is revolutionizing healthcare, and these genomic stocks are leading the way. Therefore, as this sector continues to evolve, investing in genomic stocks like Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), and Illumina (ILMN) could be beneficial. Read on….

StockNews.com

What to Expect From Regeneron Pharmaceuticals's Q4 2024 Earnings Report

Regeneron Pharmaceuticals is slated to release its fourth-quarter results next month, and analysts forecast a single-digit dip in its bottom-line figure.

Barchart

What to Expect From Regeneron Pharmaceuticals' Q4 2024 Earnings Report

Regeneron Pharmaceuticals is slated to release its fourth-quarter results next month, and analysts forecast a single-digit dip in its bottom-line figure.

Barchart

3 Biotech Stocks Innovating the Future of Medicine

The biotech industry is booming thanks to the rising demand for personalized medicine, investment in innovations, and ongoing advancements like AI. Therefore, fundamentally sound biotech stocks Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Gilead Sciences (GILD), which are at the forefront of innovation, could be ideal portfolio additions. Read more.

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

3 S&P 500 Stocks to Buy in 2025 With Big Rebound Potential

As markets rise, a handful of resilient stocks that were bruised could rebound over 30%, powered by strong fundamentals and bullish prospects.

StockNews.com

3 Biotech Innovators Advancing Genetic Therapies

The biotechnology market experiences significant growth, fueled by advancements in genetic therapies and supportive global regulations. Considering the advancements, fundamentally solid biotech stocks Gilead Sciences (GILD), Vertex Pharmaceuticals (VRTX), and Regeneron Pharmaceuticals (REGN) are emerging as top choices for investors seeking transformative opportunities. Read further….

Barchart

3 Nasdaq-100 Stocks With 25% to 53% Upside Potential

These three Nasdaq-100 Stocks shine as prime opportunities as analysts forecast 25% to 53% upside potential.

StockNews.com

3 Biotech Stocks Revolutionizing Cancer Treatment

Biotech companies are making monumental strides in cancer treatment, leveraging cutting-edge technologies to redefine the field. Given the robust prospect, investors looking for fundamentally sound biotech stocks might consider adding Regeneron Pharmaceuticals (REGN), Amgen (AMGN), and Gilead Sciences (GILD) to their portfolio. Read on….

Get all your
news in one place.

100's of premium titles.
One news app.

Barchart

Is Regeneron Pharmaceuticals Stock Underperforming the Nasdaq?

Despite Regeneron Pharmaceuticals’ significant underperformance relative to Nasdaq recently, Wall Street analysts remain strongly optimistic about the stock’s prospects.

Benzinga

Regeneron Pharmaceuticals Unusual Options Activity

Investors with a lot of money to spend have taken a bullish stance on Regeneron Pharmaceuticals (NASDAQ:REGN).

Barchart

Do Wall Street Analysts Like Regeneron Pharmaceuticals Stock?

Despite Regeneron Pharmaceuticals’ underperformance relative to the broader market over the past year, Wall Street analysts remain strongly optimistic about the stock’s prospects.

StockNews.com

3 Biotech Stocks Predicted to Surge on Medical Innovation

Biotech stocks are surging as groundbreaking neuroscience and gene therapy innovations take center stage. Amid this backdrop, investors might consider adding fundamentally strong biotech stocks like Regeneron Pharmaceuticals (REGN), Biogen (BIIB), and Gilead Sciences (GILD) to their portfolio for an impactful investment. Continue reading….

StockNews.com

3 Biotechnology Stocks With Promising Pipelines

With increasing chronic diseases, demand for personalized medicines, and adoption of AI, the biotech market is booming. Therefore, it could be wise to invest in solid biotech stocks Amgen (AMGN), Regeneron Pharmaceuticals (REGN), and Gilead Sciences (GILD) for substantial returns. Read more.

Barchart

Here's What to Expect From Regeneron Pharmaceuticals’ Next Earnings Report

Regeneron Pharmaceuticals is expected to report its fiscal third-quarter earnings this month, and analysts project a single-digit profit plunge.

StockNews.com

3 Biotech Stocks Set to Revolutionize Medicine

The biotechnology industry is rapidly evolving, with innovative companies pushing the boundaries of science and medicine. To capitalize on the industry’s expansion, it could be wise to invest in fundamentally sound biotech stocks, Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), and Biogen (BIIB), which have the potential to revolutionize medicine. Read…

1 2 3 4 5

People

Kritika SarmahHer

727 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.